# IPG Photonics Corp: financial statements, quarterly

IPGP · Nasdaq · CIK 1111928 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ipgp.md) · [Financials](/companies/ipgp/financials.md) · [Filings](/companies/ipgp/filings.md) · [Insiders](/companies/ipgp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ipgp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [301](/filings/0001111928-24-000135.md) | [299 d](/filings/0001111928-26-000040.md) | [252](/filings/0001111928-25-000069.md) | [258](/filings/0001111928-25-000132.md) | [233](/filings/0001111928-25-000168.md) | [234 d](/filings/0001111928-26-000040.md) | [228](/filings/0001111928-26-000098.md) | [251](/filings/0001111928-26-000153.md) | [251](/filings/0001111928-25-000168.md) | [274 d](/filings/0001111928-26-000040.md) | [265](/filings/0001111928-26-000098.md) | [279](/filings/0001111928-26-000153.md) |
| Cost of revenue | $m | [168](/filings/0001111928-24-000135.md) | [185 d](/filings/0001111928-26-000040.md) | [154](/filings/0001111928-25-000069.md) | [161](/filings/0001111928-25-000132.md) | [179](/filings/0001111928-25-000168.md) | [144 d](/filings/0001111928-26-000040.md) | [138](/filings/0001111928-26-000098.md) | [157](/filings/0001111928-26-000153.md) | [152](/filings/0001111928-25-000168.md) | [175 d](/filings/0001111928-26-000040.md) | [166](/filings/0001111928-26-000098.md) | [166](/filings/0001111928-26-000153.md) |
| Gross profit | $m | [133](/filings/0001111928-24-000135.md) | [114 d](/filings/0001111928-26-000040.md) | [97.5](/filings/0001111928-25-000069.md) | [96.2](/filings/0001111928-25-000132.md) | [54.1](/filings/0001111928-25-000168.md) | [90.3 d](/filings/0001111928-26-000040.md) | [89.8](/filings/0001111928-26-000098.md) | [93.6](/filings/0001111928-26-000153.md) | [99.0](/filings/0001111928-25-000168.md) | [99.1 d](/filings/0001111928-26-000040.md) | [99.5](/filings/0001111928-26-000098.md) | [113](/filings/0001111928-26-000153.md) |
| Research and development | $m | [24.7](/filings/0001111928-24-000135.md) | [27.7 d](/filings/0001111928-26-000040.md) | [29.4](/filings/0001111928-25-000069.md) | [27.5](/filings/0001111928-25-000132.md) | [27.2](/filings/0001111928-25-000168.md) | [25.7 d](/filings/0001111928-26-000040.md) | [28.3](/filings/0001111928-26-000098.md) | [29.9](/filings/0001111928-26-000153.md) | [30.4](/filings/0001111928-25-000168.md) | [28.8 d](/filings/0001111928-26-000040.md) | [33.3](/filings/0001111928-26-000098.md) | [31.0](/filings/0001111928-26-000153.md) |
| Operating income | $m | [55.7](/filings/0001111928-24-000135.md) | [28.8 d](/filings/0001111928-26-000040.md) | [19.1](/filings/0001111928-25-000069.md) | [12.0](/filings/0001111928-25-000132.md) | [(253)](/filings/0001111928-25-000168.md) | [14.0 d](/filings/0001111928-26-000040.md) | [1.8](/filings/0001111928-26-000098.md) | [0.1](/filings/0001111928-26-000153.md) | [7.9](/filings/0001111928-25-000168.md) | [3.3 d](/filings/0001111928-26-000040.md) | [(7.7)](/filings/0001111928-26-000098.md) | [4.5](/filings/0001111928-26-000153.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [12.8](/filings/0001111928-24-000135.md) | [0.7 d](/filings/0001111928-26-000040.md) | [9.5](/filings/0001111928-25-000069.md) | [4.9](/filings/0001111928-25-000132.md) | [(8.9)](/filings/0001111928-25-000168.md) | [14.2 d](/filings/0001111928-26-000040.md) | [6.9](/filings/0001111928-26-000098.md) | [1.7](/filings/0001111928-26-000153.md) | [8.2](/filings/0001111928-25-000168.md) | [(2.7) d](/filings/0001111928-26-000040.md) | [(0.6)](/filings/0001111928-26-000098.md) | [7.3](/filings/0001111928-26-000153.md) |
| Net income | $m | [55.0](/filings/0001111928-24-000135.md) | [41.4 d](/filings/0001111928-26-000040.md) | [24.1](/filings/0001111928-25-000069.md) | [20.2](/filings/0001111928-25-000132.md) | [(234)](/filings/0001111928-25-000168.md) | [7.8 d](/filings/0001111928-26-000040.md) | [3.8](/filings/0001111928-26-000098.md) | [6.6](/filings/0001111928-26-000153.md) | [7.5](/filings/0001111928-25-000168.md) | [13.3 d](/filings/0001111928-26-000040.md) | [1.6](/filings/0001111928-26-000098.md) | [5.2](/filings/0001111928-26-000153.md) |
| Diluted EPS | $ per share | [1.16](/filings/0001111928-24-000135.md) | not reported | [0.52](/filings/0001111928-25-000069.md) | [0.45](/filings/0001111928-25-000132.md) | [(5.33)](/filings/0001111928-25-000168.md) | not reported | [0.09](/filings/0001111928-26-000098.md) | [0.16](/filings/0001111928-26-000153.md) | [0.18](/filings/0001111928-25-000168.md) | not reported | [0.04](/filings/0001111928-26-000098.md) | [0.12](/filings/0001111928-26-000153.md) |
| Basic EPS | $ per share | [1.16](/filings/0001111928-24-000135.md) | not reported | [0.52](/filings/0001111928-25-000069.md) | [0.45](/filings/0001111928-25-000132.md) | [(5.33)](/filings/0001111928-25-000168.md) | not reported | [0.09](/filings/0001111928-26-000098.md) | [0.16](/filings/0001111928-26-000153.md) | [0.18](/filings/0001111928-25-000168.md) | not reported | [0.04](/filings/0001111928-26-000098.md) | [0.12](/filings/0001111928-26-000153.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [528](/filings/0001111928-23-000170.md) | [515](/filings/0001111928-25-000023.md) | [496](/filings/0001111928-24-000068.md) | [721](/filings/0001111928-24-000122.md) | [884](/filings/0001111928-24-000135.md) | [620](/filings/0001111928-26-000040.md) | [363](/filings/0001111928-25-000069.md) | [359](/filings/0001111928-25-000132.md) | [346](/filings/0001111928-25-000168.md) | [404](/filings/0001111928-26-000153.md) | [481](/filings/0001111928-26-000098.md) | [399](/filings/0001111928-26-000153.md) |
| Current assets | $m | [1,920](/filings/0001111928-23-000170.md) | [1,915](/filings/0001111928-25-000023.md) | [1,830](/filings/0001111928-24-000068.md) | [1,718](/filings/0001111928-24-000122.md) | [1,570](/filings/0001111928-24-000135.md) | [1,431](/filings/0001111928-26-000040.md) | [1,443](/filings/0001111928-25-000069.md) | [1,474](/filings/0001111928-25-000132.md) | [1,435](/filings/0001111928-25-000168.md) | [1,423](/filings/0001111928-26-000153.md) | [1,433](/filings/0001111928-26-000098.md) | [1,479](/filings/0001111928-26-000153.md) |
| Total assets | $m | [2,673](/filings/0001111928-23-000170.md) | [2,699](/filings/0001111928-25-000023.md) | [2,598](/filings/0001111928-24-000068.md) | [2,495](/filings/0001111928-24-000122.md) | [2,355](/filings/0001111928-24-000135.md) | [2,289](/filings/0001111928-26-000040.md) | [2,317](/filings/0001111928-25-000069.md) | [2,379](/filings/0001111928-25-000132.md) | [2,381](/filings/0001111928-25-000168.md) | [2,424](/filings/0001111928-26-000153.md) | [2,422](/filings/0001111928-26-000098.md) | [2,425](/filings/0001111928-26-000153.md) |
| Current liabilities | $m | [220](/filings/0001111928-23-000170.md) | [215](/filings/0001111928-25-000023.md) | [192](/filings/0001111928-24-000068.md) | [190](/filings/0001111928-24-000122.md) | [194](/filings/0001111928-24-000135.md) | [205](/filings/0001111928-26-000040.md) | [197](/filings/0001111928-25-000069.md) | [217](/filings/0001111928-25-000132.md) | [213](/filings/0001111928-25-000168.md) | [234](/filings/0001111928-26-000153.md) | [247](/filings/0001111928-26-000098.md) | [239](/filings/0001111928-26-000153.md) |
| Total liabilities | $m | [289](/filings/0001111928-23-000170.md) | [284](/filings/0001111928-25-000023.md) | [258](/filings/0001111928-24-000068.md) | [242](/filings/0001111928-24-000122.md) | [241](/filings/0001111928-24-000135.md) | [265](/filings/0001111928-26-000040.md) | [257](/filings/0001111928-25-000069.md) | [275](/filings/0001111928-25-000132.md) | [276](/filings/0001111928-25-000168.md) | [296](/filings/0001111928-26-000153.md) | [306](/filings/0001111928-26-000098.md) | [297](/filings/0001111928-26-000153.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.0](/filings/0001111928-23-000170.md) | [0.0](/filings/0001111928-24-000019.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,384](/filings/0001111928-23-000170.md) | [2,415](/filings/0001111928-26-000040.md) | [2,341](/filings/0001111928-25-000132.md) | [2,253](/filings/0001111928-25-000168.md) | [2,115](/filings/0001111928-25-000168.md) | [2,024](/filings/0001111928-26-000153.md) | [2,060](/filings/0001111928-26-000153.md) | [2,105](/filings/0001111928-26-000153.md) | [2,105](/filings/0001111928-25-000168.md) | [2,128](/filings/0001111928-26-000153.md) | [2,116](/filings/0001111928-26-000153.md) | [2,127](/filings/0001111928-26-000153.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [86.0 d](/filings/0001111928-24-000135.md) | [106 d](/filings/0001111928-26-000040.md) | [54.6](/filings/0001111928-25-000069.md) | [53.5 d](/filings/0001111928-25-000132.md) | [66.1 d](/filings/0001111928-25-000168.md) | [73.8 d](/filings/0001111928-26-000040.md) | [13.4](/filings/0001111928-26-000098.md) | [(2.2) d](/filings/0001111928-26-000153.md) | [35.3 d](/filings/0001111928-25-000168.md) | [28.8 d](/filings/0001111928-26-000040.md) | [(5.5)](/filings/0001111928-26-000098.md) | [37.8 d](/filings/0001111928-26-000153.md) |
| Capital expenditure | $m | [26.1 d](/filings/0001111928-24-000135.md) | [25.2 d](/filings/0001111928-26-000040.md) | [28.1](/filings/0001111928-25-000069.md) | [24.2 d](/filings/0001111928-25-000132.md) | [23.1 d](/filings/0001111928-25-000168.md) | [23.2 d](/filings/0001111928-26-000040.md) | [24.8](/filings/0001111928-26-000098.md) | [15.4 d](/filings/0001111928-26-000153.md) | [20.7 d](/filings/0001111928-25-000168.md) | [17.9 d](/filings/0001111928-26-000040.md) | [16.3](/filings/0001111928-26-000098.md) | [20.7 d](/filings/0001111928-26-000153.md) |
| Share repurchases | $m | [46.5 d](/filings/0001111928-24-000135.md) | [64.0 d](/filings/0001111928-26-000040.md) | [89.6](/filings/0001111928-24-000068.md) | [122 d](/filings/0001111928-24-000122.md) | [74.5 d](/filings/0001111928-24-000135.md) | [57.3 d](/filings/0001111928-26-000040.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001111928-26-000098.md) | [0.0 d](/filings/0001111928-26-000153.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.7](/filings/0001111928-23-000170.md) | [47.8](/filings/0001111928-24-000068.md) | [47.5](/filings/0001111928-24-000122.md) | [47.4](/filings/0001111928-24-000135.md) | [46.2](/filings/0001111928-25-000069.md) | [45.0](/filings/0001111928-25-000132.md) | [43.8](/filings/0001111928-25-000168.md) | [42.8](/filings/0001111928-26-000098.md) | [42.6](/filings/0001111928-26-000153.md) | [42.6](/filings/0001111928-25-000168.md) | [42.9](/filings/0001111928-26-000098.md) | [42.9](/filings/0001111928-26-000153.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,534,539 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0001111928-26-000153.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.